ID   CHLA-9
AC   CVCL_M150
SY   CHLA9
DR   cancercelllines; CVCL_M150
DR   Cell_Model_Passport; SIDM01534
DR   Cosmic; 2228220
DR   DepMap; ACH-001034
DR   GEO; GSM1676339
DR   GEO; GSM1701626
DR   GEO; GSM4368462
DR   Wikidata; Q54812509
RX   PubMed=15289350;
RX   PubMed=20922763;
RX   PubMed=24312454;
RX   PubMed=25010205;
RX   PubMed=26351324;
RX   PubMed=28196595;
WW   https://www.cccells.org/PDF_Files/Brain/CHLA-9%20Cell%20Line%20Data%20Sheet.pdf
WW   https://www.cccells.org/tables/Ewings.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Doubling time: 20 hours (PubMed=20922763); 51 hours (PubMed=24312454).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Val628insThrAspIle; Zygosity=Unspecified (PubMed=25010205).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: scRNAseq analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Thorax; UBERON=UBERON_0000915.
ST   Source(s): COG; PubMed=20922763; PubMed=24312454; PubMed=25010205
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 12,14
ST   D19S433: 12,13
ST   D21S11: 28,29
ST   D2S1338: 19,20
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 10,13
ST   FGA: 23,24
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6583 ! CHLA-10
SX   Female
AG   14Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 20
//
RX   PubMed=15289350; DOI=10.1158/0008-5472.CAN-04-0377;
RA   Batra S., Reynolds C.P., Maurer B.J.;
RT   "Fenretinide cytotoxicity for Ewing's sarcoma and primitive
RT   neuroectodermal tumor cell lines is decreased by hypoxia and
RT   synergistically enhanced by ceramide modulators.";
RL   Cancer Res. 64:5415-5424(2004).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:E80060-E80060(2013).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:E1004475-E1004475(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//